Irinotecan is an anticancer drug with a broad spectrum of activity, characterized by multistep
and complex pharmacology. Regardless of its schedule of administration, neutropenia and …

The method of generalized pairwise comparisons (GPC) is an extension of the well‐known
nonparametric Wilcoxon–Mann–Whitney test for comparing two groups of observations …

Conventional analyses of a composite of multiple time‐to‐event outcomes use the time to
the first event. However, the first event may not be the most important outcome. To address …

To handle composite endpoints, the win ratio has been applied to data analysis and design
of clinical trials. Its interpretation, however, is not always clear, and it could handle ties …

In this independent, multicenter, post-marketing study, we directly compare induction
immunosuppression versus escalation strategies on the risk of reaching the disability …

The win ratio method has received much attention in methodological research, ad hoc
analyses, and designs of prospective studies. As the primary analysis, it supported the …

Win statistics offer a new approach to the analysis of outcomes in clinical trials, allowing the
combination of time-to-event and longitudinal measurements and taking into account the …

For composite outcomes whose components can be prioritized on clinical importance, the
win ratio, the net benefit and the win odds apply that order in comparing patients pairwise to …

Background In clinical trials the study interest often lies in the comparison of a treatment to a
control regarding a time to event endpoint. A composite endpoint allows to consider several …

Background The primary end point in most heart failure (HF) trials is a composite of time to a
first worsening HF event or cardiovascular death. Prevention of recurrent events and …